Delisting Determination,The Nasdaq Stock Market, LLC,
July 17, 2009, EPIX Pharmaceuticals, Inc. The Nasdaq Stock
Market, Inc. (the Exchange) has determined to remove from
listing the common stock of EPIX Pharmaceuticals, Inc.
(the Company), effective at the opening of the
trading session on July 27, 2009. Based on a review of
the information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for
listing on the Exchange pursuant to Listing Rule
5450(b)(2)(A). The Company was notified of the Staffs
determination on November 11, 2008. The Company
requested a review of the Staffs determination before the
Listing Qualifications Hearings Panel. Upon review of the
information provided by the Company, the Panel issued a
decision on February 4, 2009, which granted the
continued listing until May 11, 2009, conditioned upon the Company
regaining compliance by that date. On May 5, 2009, at
the request of the Company, the Panel transfer its
shares from the Global to the Capital Market. The Company was
unable to regain compliance with listing standards
for that market, and on May 12, the Panel notified
the Company that it did not qualify for inclusion on the
Exchange based on its failure to comply with Listing
Rule: 5550(b)(1). Trading in the Companys securities was
suspended on May 14, 2009. The Company did not request a review
of the Panels decision by the Nasdaq Listing and Hearing
Review Council. The Listing Council did not call the
matter for review. The Panels Determination to delist
the Company became final on June 26, 2009.